Abstract
At MSKCC, over 50% of the patients presenting with gallbladder cancer have been diagnosed incidentally following elective cholecystectomy for presumed benign disease. While traditional management of incidental gallbladder cancer (IGBC) dictates re-resection with the ultimate goal of achieving cure, surgical decision-making must take into account that this malignancy is characterized by poor tumor biology with frequent distant recurrence. Since early and frequent distant recurrence is the most common cause of surgical failure, the surgical oncologist’s goal should be to selectively re-resect only those patients most likely to benefit from an operation. The astute surgeon recognizes the high-risk patients who likely have micrometastatic disease at the time of diagnosis and alters the treatment sequence, delivering neoadjuvant chemotherapy. This strategy acts as a selection tool, as those progressing at distant sites during therapy are spared the morbidity and mortality of surgery and furthermore has the potential to treat micrometastatic disease. However, a chemotherapy first approach must be applied selectively since a poor response risks local progression to unresectability and a decrease in functional status that comes from the toxicities of dual agent chemotherapy that can impair surgical candidacy. To balance these risks and benefits, two other criteria for a neoadjuvant approach must be met: i) reliable identification of those patients who are at high risk of distant recurrence and who are, therefore, most likely to benefit from a systemic therapy first approach and ii) availability of effective chemotherapy options. In this review, we will outline the data and judgement we use to select a treatment sequence at our institution.
Similar content being viewed by others
References
Aloia TA, Jarufe N, Javle M et al (2015) Gallbladder cancer: expert consensus statement. HPB (Oxford) 17:681–690
Butte JM, Gonen M, Allen PJ et al (2011) The role of laparoscopic staging in patients with incidental gallbladder cancer. HPB (Oxford) 13:463–472
D’Angelica M, Dalal KM, DeMatteo RP et al (2009) Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol 16:806–816
Bartlett DL, Fong Y, Fortner JG et al (1996) Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg 224:639–646
de Aretxabala XA, Roa IS, Burgos LA et al (1997) Curative resection in potentially resectable tumours of the gallbladder. Eur J Surg 163:419–426
Matsumoto Y, Fujii H, Aoyama H et al (1992) Surgical treatment of primary carcinoma of the gallbladder based on the histologic analysis of 48 surgical specimens. Am J Surg 163:239–245
Shirai Y, Yoshida K, Tsukada K et al (1992) Radical surgery for gallbladder carcinoma. Long-term results. Ann Surg 216:565–568
Fong Y, Jarnagin W, Blumgart LH (2000) Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg 232:557–569
Foster JM, Hoshi H, Gibbs JF et al (2007) Gallbladder cancer: defining the indications for primary radical resection and radical re-resection. Ann Surg Oncol 14:833–840
Goetze TO, Paolucci V (2010) Adequate extent in radical re-resection of incidental gallbladder carcinoma: analysis of the German Registry. Surg Endosc 24:2156–2164
Ouchi K, Mikuni J, Kakugawa Y et al (2002) Laparoscopic cholecystectomy for gallbladder carcinoma: results of a Japanese survey of 498 patients. J Hepatobiliary Pancreat Surg 9:256–260
Shirai Y, Yoshida K, Tsukada K et al (1992) Inapparent carcinoma of the gallbladder. An appraisal of a radical second operation after simple cholecystectomy. Ann Surg 215:326–331
Drouard F, Delamarre J, Capron JP (1991) Cutaneous seeding of gallbladder cancer after laparoscopic cholecystectomy. N Engl J Med 325:1316
Fong Y, Brennan MF, Turnbull A et al (1993) Gallbladder cancer discovered during laparoscopic surgery Potential for iatrogenic tumor dissemination. Arch Surg 128:1054–1056
Shih SP, Schulick RD, Cameron JL et al (2007) Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg 245:893–901
Dixon E, Vollmer CM Jr, Sahajpal A et al (2005) An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg 241:385–394
Chijiiwa K, Nakano K, Ueda J et al (2001) Surgical treatment of patients with T2 gallbladder carcinoma invading the subserosal layer. J Am Coll Surg 192:600–607
Fuks D, Regimbeau JM, Le Treut YP et al (2011) Incidental gallbladder cancer by the AFC-GBC-2009 Study Group. World J Surg 35:1887–1897
Chun YS, Pawlik TM, Vauthey JN (2018) 8th edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol 25:845–847
Hari DM, Howard JH, Leung AM et al (2013) A 21-year analysis of stage I gallbladder carcinoma: is cholecystectomy alone adequate? HPB (Oxford) 15:40–48
Butte JM, Kingham TP, Gonen M et al (2014) Residual disease predicts outcomes after definitive resection for incidental gallbladder cancer. J Am Coll Surg 219:416–429
Butte JM, Waugh E, Meneses M et al (2010) Incidental gallbladder cancer: analysis of surgical findings and survival. J Surg Oncol 102:620–625
Leung U, Pandit-Taskar N, Corvera CU et al (2014) Impact of pre-operative positron emission tomography in gallbladder cancer. HPB (Oxford) 16:1023–1030
Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778–785
Al-Batran SE, Pauligk C, Homann N et al (2017) LBA-008Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: the multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO). Ann Oncol. https://doi.org/10.1093/annonc/mdx302.007
Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20
Winter JM, Brennan MF, Tang LH et al (2012) Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol 19:169–175
Conroy T, Hammel P, Hebbar M et al (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395–2406
Katz MH, Shi Q, Ahmad SA et al (2016) Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial a021101. JAMA Surg 151:e161137
Murphy JE, Wo JY, Ryan DP et al (2018) Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol 4:963–969
Christians KK, Heimler JW, George B et al (2016) Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery 159:893–900
Ausania F, Tsirlis T, White SA et al (2013) Incidental pT2-T3 gallbladder cancer after a cholecystectomy: outcome of staging at 3 months prior to a radical resection. HPB (Oxford) 15:633–637
Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281
Ito H, Ito K, D’Angelica M et al (2011) Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. Ann Surg 254:320–325
Tran TB, Nissen NN (2015) Surgery for gallbladder cancer in the US: a need for greater lymph node clearance. J Gastrointest Oncol 6:452–458
Shindoh J, de Aretxabala X, Aloia TA et al (2015) Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg 261:733–739
Horkoff MJ, Ahmed Z, Xu Y et al (2019) Adverse outcomes after bile spillage in incidental gallbladder cancers: a population-based study. Ann Surg. https://doi.org/10.1097/SLA.0000000000003325
Nagahashi M, Shirai Y, Wakai T et al (2007) Perimuscular connective tissue contains more and larger lymphatic vessels than the shallower layers in human gallbladders. World J Gastroenterol 13:4480–4483
Fahim RB, Mc DJ, Richards JC et al (1962) Carcinoma of the gallbladder: a study of its modes of spread. Ann Surg 156:114–124
Creasy JM, Goldman DA, Dudeja V et al (2017) Systemic chemotherapy combined with resection for locally advanced gallbladder carcinoma: surgical and survival outcomes. J Am Coll Surg 224:906–916
Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20:663–673
Edeline J, Benabdelghani M, Bertaut A et al (2019) Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 37:658–667
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no disclosures to report.
Human and animal rights
This manuscript does not involve research on human subjects or animals.
Informed consent
This manuscript was a review of the literature pertaining to gallbladder cancer. Therefore, there are no issues pertaining to informed consent.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Cherkassky, L., Jarnagin, W. Selecting treatment sequence for patients with incidental gallbladder cancer: a neoadjuvant approach versus upfront surgery. Updates Surg 71, 217–225 (2019). https://doi.org/10.1007/s13304-019-00670-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13304-019-00670-z